PubMed Health⌕ Search

Biomedical subjects

I Taraba

Publications and source records attributed to I Taraba.

At least 19 recordsLinked to original sources
PubMed1995

The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients.

It is well known that the effects of human recombinant erythropoietin (rHuEPO) are dose-dependent. However, when higher doses of rHuEPO are used, the frequency of the side effects also increases. The aim of our study was to analyze the hematologic parameters and blood pressure response in hemodialysis patients treated with low initial and gradually increased rHuEPO. Sixteen regular hemodialysis patients were treated with 3 x 20 U/kg/week of rHuEPO subcutaneously during the first month. Every fourth week the dose was increased by 3 x 20 U/kg/week if the hematocrit did not rise by 2%. If the elevation was 2% or more, the dose of the rHuEPO was not changed. Blood count and blood pressure were checked every week. The antihypertensive treatment was also reviewed weekly. The hematocrit increased significantly from the second week, and 11 patients achieved the target level (30%) between Weeks 8 and 24. Two patients reached the 30% hematocrit level between Weeks 2 and 8, and another 2 patients reached the target level between Weeks 25 and 28. There was 1 nonresponder. The average rHuEPO dose needed to achieve the target hematocrit was 56.3 U/kg/week. We did not observe significant changes in the mean arterial or diastolic blood pressure. It was necessary to increase the doses of antihypertensive drugs, namely nifedipine and captopril, to control blood pressure. Encephalopathy occurred in none of the cases. The low initial dose and the gradual increase of rHuEPO treatment were beneficial to the hemodialysis patients. Although the target hematocrit took longer to achieve, high blood pressure and encephalopathy were prevented by close monitoring and administration of suitable antihypertensive treatment.

Adult↗
PubMed1990

[Acute kidney failure caused by rhabdomyolysis].

Rhabdomyolysis developed in the muscles of the left lower extremity of a 43 year old man leading to myoglobinuria and acute renal failure. The diagnosis of rhabdomyolysis was strengthened by muscle and renal biopsy. The renal functions were restituted after peritoneal dialysis performed four times (12 hours each) within two weeks. The possible role of alcohol or Dalgol intoxication as well the disturbed circulation in the development of rhabdomyolysis is discussed. Authors point out the benefit of peritoneal dialysis in acute renal failure caused by rhabdomyolysis.

Acute Kidney Injury↗
PubMed1990

Changes of arterial prostaglandin E2 during haemodialysis.

The absence of a reduction in peripheral vascular resistance secondary to hypervolaemia leads to so-called volume hypertension. In order to study whether a deficient formation of the vasodilator autacoid prostaglandin E2 (PGE2) contributes to the preservation of inadequate vascular tone during extracellular volume expansion, arterial plasma PGE2 and the stable PGE2 metabolite 13,14-dihydro-15-keto-PGE2 (PGE2-M) were determined in 13 oligoanuric women on chronic haemodialysis. Prior to treatment eight of them had hypervolaemia and hypertension (mean arterial pressure (MAP) 128 +/- 3 mmHg (mean +/- SE] and five patients had hypervolaemia of a similar degree but were not hypertensive (MAP: 99 +/- 4 mmHg P less than 0.005). Before haemodialysis the arterial PGE2 and PGE2-M concentrations were less (P less than 0.05) in hypertensive (11 observations in eight patients) than in normotensive patients (ten observations in five patients). As blood pressure decreased during the course of haemodialysis of volume hypertensive patients, the concentration of PGE2 and PGE2-M increased (P less than 0.02) by 104 +/- 43% and 89 +/- 32%, respectively. In normotensive patients neither blood pressure nor the concentration of PGE2 and PGE2-M were found to change during treatment. Since volume hypertension was associated with reduced values and dialysis induced normalisation of blood pressure with increased arterial values of PGE2 and PGE2-M, we hypothesise that the development of hypertension associated with fluid overload of haemodialysed patients may be related to a decreased release of prostaglandin E2.

Adolescent↗
PubMed1989

[Myocardial calcification in chronic renal failure].

The authors present the case of a young man who--as a consequence of chronic renal failure and long-term dialysis--developed a calcific cardiopathy. The myocardial calcification was proved histologically by light microscopy. They established that the calcification started in damaged myofibers and was principally caused by the secondary parathyroid hyperfunction. The diagnosis and therapy of the myocardial calcification is discussed on the basis of references. The prevention of this complication may improve the life-expectancy of patients treated by chronic dialysis.

Adult↗
PubMed1985

Dialysis treatment in multiple myeloma.

The histories of three patients suffering from acute renal failure and multiple myeloma are reviewed. In two patients oliguric acute renal failure appeared following intravenous urography. Although renal failure was treated by dialysis, all the three patients died of pulmonary infection. It is concluded that prevention of renal failure is still more promising than its treatment.

Acute Kidney Injury↗
PubMed1985

[Peritoneal dialysis in chronic renal insufficiency].

The author reviews a possibility of the use of peritoneal dialysis in the treatment of patients with chronic renal failure. Demonstrates that this procedure compares very favourably with chronic hemodialysis (less economic losses, simplicity, no burden of the heart). Recommends the performance of the automatized procedure 3 to 5 times a week, with each session lasting 10 to 12 h.

Humans↗
PubMed1984

Short-time peritoneal dialysis.

On the evidence of observations comprising approximately 200 treatments by peritoneal dialysis (PD), the advantages of the weekly 3 X 9-h schedule over the 2 X 24-h schedule are pointed out. Utilization of dialysing fluid per week was 45.11 versus 54.61. The improved general condition of the patients and the favourable changes of the biochemical parameters were in support of this dialysis strategy. The use of the type PDK-8 automated apparatus designed by the authors, is recommended as being simple to handle, labour-saving and apt to minimize the hazard of peritonitis.

Creatinine↗
PubMed1984

Statistical analysis of monitoring examinations in chronic peritoneal dialysis program.

In dialysis centres the major part of laboratory tests is indicated by the routine monitoring strategy of the centre and not by the evidence of a new complication to be diagnosed. The aim of our study was to define an improved strategy, minimizing financial costs without loss of information. Findings of routine laboratory check-up of eleven patients undergoing chronic intermittent peritoneal dialysis were analysed. Using univariate and multivariate functions a considerable part of the laboratory test results can be estimated or predicted. From pre-dialysis measurements on serum the post-dialysis serum creatinine urea and uric acid levels can be predicted. The serum level of protein and hemoglobin can be estimated using the results of previous tests (performed maximum 7 weeks earlier) and current measurements on dialysate.

Blood Chemical Analysis↗
PubMed1982

Effect of haemodialysis on the antibody-dependent and spontaneous cell-mediated cytotoxicity of patients with chronic renal failure.

Antibody-dependent and spontaneous lymphocytotoxicity of blood mononuclear cells from 10 patients with chronic renal failure was studied before and after haemodialysis in xenogeneic chicken erythrocyte and allogeneic K-562 test systems. The originally impaired antibody-dependent and spontaneous lymphocytoxicity of uraemic patients significantly improved following haemodialysis. Both pre- and post-haemodialysis uraemic sera strongly inhibited the antibody-dependent and spontaneous cytotoxicity of autologous and of healthy control lymphocytes.

Adult↗